Afton Scientific

The biotech industry continues to push the limits of innovation, developing groundbreaking therapies that improve patient outcomes. However, even the most promising companies run into the same wall: scaling production and bringing products to market is di

What the Backend Actually Looks Like Once a sterile injectable fill is complete, the product is not ready to ship. It is at the beginning of a distinct phase with its own sequence, dependencies, and timeline. From a fill/finish perspective, that sequence

The first 90 days of a fill/finish CDMO engagement aren't administrative onboarding. Patterns are established early on how both parties communicate in this period, how they handle the first unexpected problem, whether the CDMO shows up as a genuine partne

A pharmaceutical manufacturer's decision to stay with their CDMO through commercialization or switch to a different partner is one of the most important decisions in a drug development program. It affects the timeline, regulatory risk, budget, and chances

The drug substance-to-fill-finish handoff is one of the most consequential transitions in a drug development program, and one that all parties are navigating together, often with an incomplete picture of the product. For new or early-phase formulations, t

When evaluating a relationship with a contract development and manufacturing organization (CDMO) for sterile injectable products, price and capacity are the natural starting point. However, treat them as a starting point in a partnership that can minimize

The revised Annex 1 is clear: sterility cannot be tested into a product. Manufacturers must design sterility into each step of the process, supported by appropriate controls and validation. For those focused on the visible elements of a sterile fill-finis

Strategic partnerships in the pharmaceutical industry, a response to the increasing complexity and innovation, have evolved from transactional engagements into collaborative alliances. These alliances not only drive mutual value, speed, and innovation but

Annex 1 details the requirements for manufacturing sterile pharmaceutical products intended for distribution in the European Union. Many of the principles and standards included are consistent with expectations from other regulatory bodies, including the

In aseptic pharmaceutical manufacturing, demonstrating that products are truly sterile requires more than final testing. As sterility testing is a destructive process, sterility of the entire batch is not possible. Therefore, the principles of sterile (or